Pearl IRB and Trafalgar Ethics Board Partner to Deliver Integrated US-Canada IRB Review Services
Pearl IRB,LLC and Trafalgar Ethics Board, Inc. announce a partnership to provide one stop shop service for central IRB (Institutional Review Board) services for clients. The trend for research sponsors to conduct multi-center global clinical trials continues to grow, with the United States and Canada accounting for 60.5%1 of sponsored clinical trials in 2010. Pearl IRB, based in the United States in Indianapolis and Trafalgar Ethics Board headquartered in the Toronto area in Canada, join forces to deliver integrated United States–Canada study reviews.
“We have partnered to serve the needs of our clients in a more streamlined fashion,” shares Ali Thompson, Director of Trafalgar Ethics Board. “Both our Canadian clients and US based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials. By working together to provide United States–Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”
Clinical trials are often delayed for many reasons including contract negotiations, budgeting issues, and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel US and Canadian site reviews, states Diana Caldwell, President and CEO of Pearl IRB. “Additionally, we will partner to offer additional services that are of high value to our clients including medical writing, GCP/ICH assistance, and site training all of which reach across Canada and the US now.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
